CompletedPhase 1NCT02314377
Bevacizumab Therapy for Brain Arteriovenous Malformation
Studying Brain arteriovenous malformation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Daniel Cooke, MDUCSF Medical Center
- Intervention
- Bevacizumab(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2016 – 2019
Study locations (1)
- University of California San Francisco, San Francisco, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02314377 on ClinicalTrials.govOther trials for Brain arteriovenous malformation
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07519876Pulmonary Embolism and Right-to-Left ShuntsTufts Medical Center
- RECRUITINGPHASE2, PHASE3NCT06264531Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous MalformationsFondation Ophtalmologique Adolphe de Rothschild
- RECRUITINGNCT07118631Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation BleedingBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06913725An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous MalformationsXuanwu Hospital, Beijing
- RECRUITINGNANCT07314047The Liquid Embolic Agent for the Treatment of Brain Arteriovenous MalformationMicroPort NeuroTech Co., Ltd.
- RECRUITINGNCT06259292Comprehensive HHT Outcomes Registry of the United States (CHORUS)Cure HHT
- RECRUITINGNCT05449106Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CTBeijing Tiantan Hospital
- RECRUITINGNCT04927156Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up PlatformBalt Extrusion